How a skin 'glue' protein (Desmoglein 1) affects pigment cell behavior and melanoma

Role of Desmoglein 1 in Keratinocyte-Melanocyte Communication and Melanoma

['FUNDING_R01'] · NORTHWESTERN UNIVERSITY · NIH-11284089

Looks at whether losing a skin adhesion protein changes how pigment cells behave and may help cause melanoma, with the goal of helping people at risk for or living with melanoma.

Quick facts

Phase['FUNDING_R01']
Study typeNih_funding
SexAll
SponsorNORTHWESTERN UNIVERSITY (nih funded)
Locations1 site (CHICAGO, UNITED STATES)
Trial IDNIH-11284089 on ClinicalTrials.gov

What this research studies

From a patient perspective, researchers will explore how a keratinocyte protein called Desmoglein 1 (Dsg1) influences nearby pigment cells (melanocytes) and whether its loss creates conditions that encourage melanoma. They will use lab-grown skin models, cultured cells, and animal models to mimic short-term and chronic loss of Dsg1 and measure changes in cell signaling, inflammation, and pigment cell behavior. The team will study contact-based and secreted (paracrine) signals between keratinocytes and melanocytes and follow stage-wise changes that could lead to transformation. Findings are intended to clarify non-genetic factors that cooperate with known melanoma mutations and point to new targets to prevent or slow tumor progression.

Who could benefit from this research

Good fit: People with a history of significant sun damage, atypical moles, or prior melanoma would be most relevant to follow-up studies or sample donation related to this work.

Not a fit: Patients with non-skin cancers or those needing immediate clinical treatment for advanced metastatic melanoma are unlikely to gain direct, near-term benefit from this laboratory-focused research.

Why it matters

Potential benefit: If successful, this work could identify new ways to detect, prevent, or interrupt early steps in melanoma by targeting keratinocyte–melanocyte signaling.

How similar studies have performed: Previous laboratory studies showed Dsg1 loss can trigger tanning responses and inflammation, but linking chronic Dsg1 loss to melanoma development is a newer, less-tested idea.

Where this research is happening

CHICAGO, UNITED STATES

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.

View on NIH RePORTER →

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.